Table 1.
Clinico-pathological features of patients.
Figure 1.
Colon cancer sections immunostained for the evaluation of MCDPT and MVD at x400 magnification, high MCDPT and MVD respectively.
In A a primary anti-tryptase antibody has been employed. Arrows indicate red mast cells positive to tryptase. In B a primary anti CD-34 antibody has been employed. Arrows indicate red positive microvessels.
Figure 2.
Colon cancer sections immunostained for the detail evaluation of MCDPT and MVD at x1000 magnification in oil respectively.
In A a primary anti-tryptase antibody has been employed. The big arrows indicate single red mast cells positive to tryptase. The small arrow indicates the degranulation front of the mast cell forming a microvessel. In B a primary anti CD-34 antibody has been employed. The big arrow indicates a red positive microvessel. The small arrow indicates the nucleus of the endothelial cell. Note the lumen of the microvessel.
Figure 3.
Adjacent normal mucosa section and colon cancer section immunostained for the evaluation of MCDPT and VEGF expression at x400 magnification respectively.
In A a primary anti-tryptase antibody has been employed. Arrow indicates a single and unique red mast cells positive to tryptase in the observed field. In B a primary anti-VEGF antibody has been employed. Many red immunostained cancer cells. Big arrows indicate single red cytoplasmic cancer cells positive to VEGF.
Figure 4.
Differences between STLBS (red line) and STLAS (blu line).
Figure 5.
Correlation analysis between MVD and STLBS.
Figure 6.
Correlation analysis between MCDPT and STLBS.
Figure 7.
Correlation analysis between MVD and MCDPT.
Table 2.
STLBS, STLAS, MCDPT and MVD means ±1 standard deviations in a series of 61 colo-rectal cancer patients.